| LMT |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$7.30 vs. cons $7.15 |
MEDIUM |
| LMT |
Report |
Q2 2026 Net Sales |
IN-LINE |
pred ~$19.40B vs. cons $19.28B |
MEDIUM |
| LMT |
Report |
Q2 2026 Free Cash Flow |
MISS |
pred ~$150M vs. cons ~$450M |
LOW |
| LMT |
Guide |
FY2026 Diluted EPS Guidance |
UNCHANGED |
guide ~$29.80 (midpoint of $29.35-$30.25) vs. cons ~$29.85 (FY2026) |
MEDIUM |
| LMT |
Guide |
FY2026 Net Sales Guidance |
UNCHANGED |
guide ~$78.75B (midpoint of $77.5-80.0B) vs. cons ~$78.9B (FY2026) |
MEDIUM |
| LMT |
Guide |
FY2026 Free Cash Flow Guidance |
UNCHANGED |
guide ~$6.65B (midpoint of $6.5-6.8B) vs. cons ~$6.6B (FY2026) |
LOW |
| LMT |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| LMT |
Return |
5-day cumulative residual |
-0.5% (FADE) |
An EPS beat driven by absence of new classified-program charges plus reaffirmed FY26 guidance likely sparks a relief rally on day 1 given how depressed sentiment/positioning was going in. But FCF remains soft (still below the pace needed to hit the $6.5-6.8B FY target given a negative Q1 and only modest Q2 recovery), and the FY guide implies a very back-half-loaded ramp in both margins and cash generation. As sell-side models the out-quarters, analysts are likely to trim near-term FCF/margin estimates even after a headline EPS beat, since the 'growing pains' (F-16, C-130, Sikorsky, ERP drag) aren't fully resolved — causing the initial pop to partially fade over the following days as the quality of the beat is scrutinized. |
LOW |